Evidence map›Paper›PMID 30392153›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2019

The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.

X Ni, X Sun, D Wang, Y Chen, Y Zhang, W Li, L Wang, J Suo

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

X NiDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China.
X SunDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China.
D WangDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China.
Y ChenDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China.
Y ZhangDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China.
W LiDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China.
L WangDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China.
J SuoDepartment of Gastrointestinal Surgery, First Hospital of Jilin University, 71 Xinmin Street, Chaoyang District, Changchun, 130021, China. suojian24@hotmail.com.ORCID http://orcid.org/0000-0002-0323-4262

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProgrammed death-ligand 1 (PD-L1) is reportedly expressed in colorectal tumors. However, the prognostic role of PD-L1 in colorectal cancer (CRC) remains controversial. Therefore, we performed a meta-analysis to investigate the clinicopathological and prognostic impact of PD-L1 in CRC.

methodsA comprehensive search in PubMed, Embase, the Cochrane Library, Web of Science and the ClinicalTrials.gov for publications about PD-L1 expression in colorectal cancer was done. The correlation between PD-L1 expression and clinicopathological features or survival outcomes was analyzed by odds ratios (OR) or hazard ratios (HR), at 95% confidence intervals (CI).

resultsThe results show that the pooled HR of (1.34, 95% CI 1.02-1.65, p = 0.01) indicated the association of PD-L1 expression with overall survival (OS) in CRC patients. Meanwhile, the expression of PD-L1 was positively correlated with the lymph node metastasis (OR: 0.70, 95% CI 0.51-0.95, p = 0.00), gender (OR: 0.86, 95% CI 0.76-0.98, p = 0.05) and tumor location (OR: 1.39, 95% CI 1.14-1.71, p = 0.12).

conclusionsThese results suggest that high expression of PD-L1 is associated with low OS in CRC. High PD-L1 expression may act as a negative factor for patients with CRC and help to identify patients suitable for anticancer therapy.

Indexed as

B7-H1 AntigenBiomarkers, TumorColorectal NeoplasmsHumansPrognosisSurvival RateB7-H1 AntigenBiomarkers, TumorCD274 protein, humanColorectal cancerMeta-analysisPrognosisProgrammed death-ligand 1

Identifiers

PMID30392153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.